Alternatives to tofacitinib
2 same-class SPL records vs tofacitinib - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Xeljanz
How to read a high-report FAERS peer set
tofacitinib ranks in the upper FAERS-volume third of the corpus (#34 of 524); 2 same-class peers are listed for field comparison only. Labeled indication field for tofacitinib: Xeljanz treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults.
Top FAERS reaction fields for tofacitinib total 160,804 reports across 10 reactions, set beside baricitinib, upadacitinib. Counts are exposure-weighted submissions, not per-patient risk.
About tofacitinib
Xeljanz is a medicine that reduces inflammation in your body. It is used to treat conditions like arthritis and ulcerative colitis.
Used for: Xeljanz treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults. It is also used to treat psoriatic arthritis and juvenile idiopathic arthritis in children 2 years and older. It is for people who have not responded well to TNF blockers. Do not use Xeljanz with other strong immunosuppressants.
2 JAK Inhibitor peers (wide set)
baricitinib
RxOlumiant
Olumiant treats rheumatoid arthritis in adults when other medicines have not worked well. Rheumatoid arthritis is a disease that causes pain, swelling, and stiffness in the joints. Olumiant can also be used to treat alopecia areata, a condition that causes patchy hair loss.
upadacitinib
RxRinvoq
Rinvoq can treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. It is used when other medicines, like TNF blockers, have not worked well enough. For ulcerative colitis and Crohn's disease, you should have tried at least one other approved medicine before using Rinvoq if TNF blockers are not suitable for you.
tofacitinib vs baricitinib & upadacitinib · FAERS reaction fields
FAERS top-reaction field "Pain" shows the widest count spread between tofacitinib and baricitinib, upadacitinib in this extract (20,795-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | tofacitinib | baricitinib | upadacitinib |
|---|---|---|---|
| Pain | 25,737 | 173 | 4,942 |
| Arthralgia | 19,670 | 179 | 4,342 |
| Condition Aggravated | 19,467 | - | - |
| Rheumatoid Arthritis | 18,797 | 352 | 3,037 |
| Fatigue | 16,595 | 183 | 2,433 |
| Joint Swelling | 14,455 | - | - |
| Headache | 13,405 | 253 | 1,792 |
| Rash | 11,912 | 156 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
tofacitinib FAERS volume vs class peers
FAERS volume band
tofacitinib is FAERS corpus rank #34 of 524 (high volume tercile). Top-reaction field total: 160,804.
Frequently Asked Questions
Where does tofacitinib sit in FAERS report volume vs JAK Inhibitor peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for tofacitinib: see also the generic vs brand label guide when reading Xeljanz SPL strings.
Read our methodology - how this data is sourced, computed, and verified.